Brilliant Violet 711™ anti-human HLA-DR

Antibodies Single
Sony
L243
Flow Cytometry
Mouse IgG2a, κ
Human
2138220
$462.00

Description

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Brodsky F. 1984. Immunogenetics 19:179.
2. Robbins P, et al. 1987. Human Immunol. 18:301.
3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
6. Zipf T, et al. 1981. Cancer Res. 41:4786.
7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
10. Wang RF, et al. 1999. Science 284:1351. (Block)
11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
19. Moro M, et al. 2005. BMC Immunol. 6:24.
20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed